🚀 VC round data is live in beta, check it out!
BoneSupport Valuation Multiples
Discover revenue and EBITDA valuation multiples for BoneSupport and similar public comparables like VCANBIO, Heron Neutron Medical, Embla Medical, Beijing Balance Medical and more.
BoneSupport Overview
About BoneSupport
Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and sells injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. Its products focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: North America (NA) and Europe & Rest of the World (EUROW).
Founded
1999
HQ
Employees
127
Website
Financials (LTM)
EV
$2B
BoneSupport Financials
BoneSupport reported last 12-month revenue of $140M and EBITDA of $32M.
In the same LTM period, BoneSupport generated $130M in gross profit, $32M in EBITDA, and $22M in net income.
Revenue (LTM)
BoneSupport P&L
In the most recent fiscal year, BoneSupport reported revenue of $130M and EBITDA of $26M.
BoneSupport expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $140M | XXX | $130M | XXX | XXX | XXX |
| Gross Profit | $130M | XXX | $118M | XXX | XXX | XXX |
| Gross Margin | 93% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | $32M | XXX | $26M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $22M | XXX | $16M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 13% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BoneSupport Stock Performance
BoneSupport has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
BoneSupport's stock price is $29.26.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.1% | XXX | XXX | XXX | $0.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBoneSupport Valuation Multiples
BoneSupport trades at 13.4x EV/Revenue multiple, and 58.5x EV/EBITDA.
EV / Revenue (LTM)
BoneSupport Financial Valuation Multiples
As of April 19, 2026, BoneSupport has market cap of $2B and EV of $2B.
Equity research analysts estimate BoneSupport's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BoneSupport has a P/E ratio of 89.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 13.4x | XXX | 14.6x | XXX | XXX | XXX |
| EV/EBITDA | 58.5x | XXX | 71.2x | XXX | XXX | XXX |
| EV/EBIT | 58.5x | XXX | 62.5x | XXX | XXX | XXX |
| EV/Gross Profit | 14.5x | XXX | 16.0x | XXX | XXX | XXX |
| P/E | 89.1x | XXX | 118.9x | XXX | XXX | XXX |
| EV/FCF | 81.5x | XXX | 80.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BoneSupport Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BoneSupport Margins & Growth Rates
BoneSupport's revenue in the last 12 month grew by 29%.
BoneSupport's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $0.7M for the same period.
BoneSupport's rule of 40 is 58% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BoneSupport's rule of X is 102% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BoneSupport Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 29% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 67% | XXX | 74% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 58% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 102% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 51% | XXX | 52% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 8% | XXX | 8% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 68% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BoneSupport Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| BoneSupport | XXX | XXX | XXX | XXX | XXX | XXX |
| VCANBIO | XXX | XXX | XXX | XXX | XXX | XXX |
| Heron Neutron Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Embla Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Beijing Balance Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Draegerwerk | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BoneSupport M&A Activity
BoneSupport acquired XXX companies to date.
Last acquisition by BoneSupport was on XXXXXXXX, XXXXX. BoneSupport acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BoneSupport
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBoneSupport Investment Activity
BoneSupport invested in XXX companies to date.
BoneSupport made its latest investment on XXXXXXXX, XXXXX. BoneSupport invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BoneSupport
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BoneSupport
| When was BoneSupport founded? | BoneSupport was founded in 1999. |
| Where is BoneSupport headquartered? | BoneSupport is headquartered in Sweden. |
| How many employees does BoneSupport have? | As of today, BoneSupport has over 127 employees. |
| Who is the CEO of BoneSupport? | BoneSupport's CEO is Emil Billback. |
| Is BoneSupport publicly listed? | Yes, BoneSupport is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of BoneSupport? | BoneSupport trades under BONEX ticker. |
| When did BoneSupport go public? | BoneSupport went public in 2017. |
| Who are competitors of BoneSupport? | BoneSupport main competitors are VCANBIO, Heron Neutron Medical, Embla Medical, Beijing Balance Medical. |
| What is the current market cap of BoneSupport? | BoneSupport's current market cap is $2B. |
| What is the current revenue of BoneSupport? | BoneSupport's last 12 months revenue is $140M. |
| What is the current revenue growth of BoneSupport? | BoneSupport revenue growth (NTM/LTM) is 29%. |
| What is the current EV/Revenue multiple of BoneSupport? | Current revenue multiple of BoneSupport is 13.4x. |
| Is BoneSupport profitable? | Yes, BoneSupport is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BoneSupport? | BoneSupport's last 12 months EBITDA is $32M. |
| What is BoneSupport's EBITDA margin? | BoneSupport's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of BoneSupport? | Current EBITDA multiple of BoneSupport is 58.5x. |
| What is the current FCF of BoneSupport? | BoneSupport's last 12 months FCF is $23M. |
| What is BoneSupport's FCF margin? | BoneSupport's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of BoneSupport? | Current FCF multiple of BoneSupport is 81.5x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.